Publication

Article

July 15, 2006

The American Journal of Managed Care

July 2006

Volume12

Issue 7

Brixner (Am J Manag Care. 2006;12[suppl 7]:S191-S198)

Am J Manag Care.

There were 2 errors in the supplement, "Fracture Prevention in Osteoporosis." First, in Figure 1 on page S192 of the article "Assessment of the Prevalence and Costs of Osteoporosis Treatment Options in a Real-world Setting," by Diana Brixner, PhD, RPh,(2006;12[suppl 7]:S191-S198), the bars representing the VERTNA [Vertebral Efficacy With Risedronate Therapy-North America] study were inadvertently switched with the placebo bars. Second, in the same figure, the acronym VERT-MIN was incorrect; the correct acronym is VERT-MN [Vertebral Efficacy With Risedronate Therapy-Multinational]. The corrected figure appears below.

Download PDF: Brixner (Am J Manag Care. 2006;12[suppl 7]:S191-S198)

Articles in this issue

Brixner (Am J Manag Care. 2006;12[suppl 7]:S191-S198)

Selecting an appropriate comparator to measure osteoarthritic pain

Outpatient Management of Deep Venous Thrombosis: 2 Models of Integrated Care

Insurance Coverage and Subsequent Utilization of Complementary and Alternative Medicine Providers

Evaluation of Laboratory Monitoring Alerts Within a Computerized Physician Order Entry System for Medication Orders

Cost-effectiveness of Extended Adjuvant Letrozole Therapy After 5 Years of Adjuvant Tamoxifen Therapy in Postmenopausal Women With Early-stage Breast Cancer

Defending Computerized Physician Order Entry From Its Supporters

Computerized Physician Order Entry and Clinical Decision Support Systems: Early Stages in Demonstrating Improvements in Patient Outcomes

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos

Related Content

AJMC

July 24th 2025

Prevalence and Inclusiveness of Pay-for-Performance Incentives for HPV Vaccination

Justin G. Trogdon, PhD Kathryn R. Brignole, MS Ben Fogel, MD, MPH Tara Licciardello Queen, PhD

This article examines the prevalence of pay-for-performance incentives to promote human papillomavirus vaccination and other quality metrics as reported by frontline clinical staff.

AJMC

July 23rd 2025

Effects of Adjunctive Cariprazine Formulary Restrictions in Major Depressive Disorder

Nadia Nabulsi, PhD François Laliberté, MA Enrico Zanardo, PhD Sean D. MacKnight, MScPH Sophie Ma, MSc Sally W. Wade, MPH Mousam Parikh, MSc

Patients who experienced a formulary-related rejection of cariprazine for adjunctive treatment of major depressive disorder had significantly higher hospitalization rates than those with approved claims.

AJMC

July 18th 2025

Assertive Community Treatment for Complex and Costly Patients

Trygve Dolber, MD Patrick Runnels, MD, MBA Peter J. Pronovost, MD, PhD

Assertive community treatment, a strongly evidence-based practice for delivering care to individuals with schizophrenia and low health care engagement, is applicable to disengaged, medically complex patients.

AJMC

July 10th 2025

High-Risk Care Management Impact on Medicaid ACO Utilization and Spending

Kathryn Corelli, MD Erin Duralde, MD Diya Mathur, BA Mary Price, MA Nicole M. Benson, MD, MBI Nishmi Abeyweera, AB Vicki Fung, PhD Christine Vogeli, PhD Katherine H. Schiavoni, MD, MPP Maryann M. Vienneau, BS Mallika L. Mendu, MD, MBA Lindsay Jubelt, MD, MS Gregg S. Meyer, MD, MSc John Hsu, MD, MBA, MSCE

In Massachusetts’ largest Medicaid accountable care organization (ACO), high-risk care management significantly reduced spending, emergency department visits, and hospitalizations, demonstrating that targeted strategies can manage health care costs amid budget constraints.

AJMC

July 9th 2025

Trends in Market Share Among Hospitals Participating in ACOs and Nonparticipants

Mariétou H. Ouayogodé, PhD Xiaodan Liang, MS David B. Muhlestein, PhD, JD

Accountable care organization (ACO) participation was associated with an increase in hospitals’ mean market share and with additional market share gains in more concentrated markets.

AJMC

July 8th 2025

Corticosteroid Premedication for Infliximab Remains Unnecessarily Common

Shirley Cohen-Mekelburg, MD, MS Jeffrey Gibbs, MD Beth Wallace, MD, MS Brooke Kenney, MPH Akbar K. Waljee, MD, MSc

Although use of corticosteroid premedication prior to infliximab infusions is declining, it remains unnecessarily high despite limited benefit and the risk of serious adverse events from corticosteroids.

Related Content

AJMC

July 24th 2025

Prevalence and Inclusiveness of Pay-for-Performance Incentives for HPV Vaccination

Justin G. Trogdon, PhD Kathryn R. Brignole, MS Ben Fogel, MD, MPH Tara Licciardello Queen, PhD

This article examines the prevalence of pay-for-performance incentives to promote human papillomavirus vaccination and other quality metrics as reported by frontline clinical staff.

AJMC

July 23rd 2025

Effects of Adjunctive Cariprazine Formulary Restrictions in Major Depressive Disorder

Nadia Nabulsi, PhD François Laliberté, MA Enrico Zanardo, PhD Sean D. MacKnight, MScPH Sophie Ma, MSc Sally W. Wade, MPH Mousam Parikh, MSc

Patients who experienced a formulary-related rejection of cariprazine for adjunctive treatment of major depressive disorder had significantly higher hospitalization rates than those with approved claims.

AJMC

July 18th 2025

Assertive Community Treatment for Complex and Costly Patients

Trygve Dolber, MD Patrick Runnels, MD, MBA Peter J. Pronovost, MD, PhD

Assertive community treatment, a strongly evidence-based practice for delivering care to individuals with schizophrenia and low health care engagement, is applicable to disengaged, medically complex patients.

AJMC

July 10th 2025

High-Risk Care Management Impact on Medicaid ACO Utilization and Spending

Kathryn Corelli, MD Erin Duralde, MD Diya Mathur, BA Mary Price, MA Nicole M. Benson, MD, MBI Nishmi Abeyweera, AB Vicki Fung, PhD Christine Vogeli, PhD Katherine H. Schiavoni, MD, MPP Maryann M. Vienneau, BS Mallika L. Mendu, MD, MBA Lindsay Jubelt, MD, MS Gregg S. Meyer, MD, MSc John Hsu, MD, MBA, MSCE

In Massachusetts’ largest Medicaid accountable care organization (ACO), high-risk care management significantly reduced spending, emergency department visits, and hospitalizations, demonstrating that targeted strategies can manage health care costs amid budget constraints.

AJMC

July 9th 2025

Trends in Market Share Among Hospitals Participating in ACOs and Nonparticipants

Mariétou H. Ouayogodé, PhD Xiaodan Liang, MS David B. Muhlestein, PhD, JD

Accountable care organization (ACO) participation was associated with an increase in hospitals’ mean market share and with additional market share gains in more concentrated markets.

AJMC

July 8th 2025

Corticosteroid Premedication for Infliximab Remains Unnecessarily Common

Shirley Cohen-Mekelburg, MD, MS Jeffrey Gibbs, MD Beth Wallace, MD, MS Brooke Kenney, MPH Akbar K. Waljee, MD, MSc

Although use of corticosteroid premedication prior to infliximab infusions is declining, it remains unnecessarily high despite limited benefit and the risk of serious adverse events from corticosteroids.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions